Mucins and Mucosal protection in the Gastrointestinal Tract: New Prospects for Mucins in the Pathology of Gastrointestinal Disease
Karimzadeh MA, Eftekhar M, Taheripanah R, Tayebi N, Sakhavat L, Zare F
TODAY cited data from Americas Poison Centers showing an almost 1,500% increase in calls related to overdoses or side effects involving injectable GLP-1 weight loss drugs between 2019 and 2025, with nearly 23,000 reported cases during that period
Finally, future research should explore how GLP-1 RAs could be integrated into current clinical pathways for addiction care, especially in settings where diabetes, obesity, and SUD frequently co-occur
Semaglutide, liraglutide, and dulaglutide have all demonstrated modest systolic blood pressure reductions in clinical studies
The metabolic stack combines MOTS-C with NAD+